Results 221 to 230 of about 4,862,841 (293)

Genetic and Population Analyses Implicate Thyroid‐Related Regulation of RNF144B in Chondrocalcinosis

Arthritis &Rheumatology, EarlyView.
Objective Chondrocalcinosis, characterized by calcium crystal deposition within articular cartilage, affects 5% to 15% of the general population and has recently been identified as an osteoarthritis risk factor. However, its biologic pathways remain unclear.
Yahong Wu, Yanning Xu, Paul C. Okoro, Sirine Saafi, Jard de Vries, Xiaoyi Qi, Edwin H. G. Oei, Sita Bierma‐Zeinstra, Trudy Voortman, David Felson, Joyce B. J. van Meurs, Layal Chaker, J. Mark Wilkinson, Michelle S. Yau, Jessica Bertrand, Cindy G. Boer   +15 more
wiley   +1 more source

Detection, virus isolation, and phylogenetic analysis of PRRSV2 in China from 2022 to 2025. [PDF]

Porcine Health Manag
Yang H, Song W, Chu D, Li Z, Zhu Z, Xie R, Hua L, Chen H, Wu B, Peng Z.   +9 more
europepmc   +1 more source

Development of a nalmefene formulation suitable for a community‐use auto‐injector

British Journal of Clinical Pharmacology, EarlyView.
Aim Time to onset of reversal is critical when treating opioid‐induced respiratory depression and hypoxia. This study aimed to develop a formulation of the opioid antagonist nalmefene with an increased absorption rate and reduced time to onset of reversal following intramuscular administration. Methods Several absorption enhancers were screened in rats,
Alessandra Cipriano, Manjunath S. Shet, Hugh Huang, Ronnie Ortiz, Garth T. Whiteside, Glen Apseloff, Stephen C. Harris   +6 more
wiley   +1 more source

Lamin subtype expression in Merkel-cell carcinoma: its relation to polyomavirus infection and tumor metastasis. [PDF]

Histochem Cell Biol
Stiekema M, Ummelen M, Jesinghaus M, Keber CU, Wischmann V, Moll I, Cleutjens J, van Zandvoort MAMJ, Broers JLV, Ramaekers FCS, Moll R.   +10 more
europepmc   +1 more source

Model‐informed optimal dose selection of golcadomide in combination with R‐CHOP in patients with previously untreated aggressive B‐cell lymphoma

British Journal of Clinical Pharmacology, EarlyView.
Aims Golcadomide is a potential first‐in‐class oral CELMoD™ agent for the treatment of lymphoma. This study aims to develop model‐informed drug development (MIDD) approaches to support optimal dose selection of golcadomide in combination with immunotherapy rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) in alignment with ...
Xirong Zheng, Zhiling Yu, Mark Kaplan, Argyrios Gkasiamis, Akshay Sudhindra, Li Zhu, Manisha Lamba, Fan Wu   +7 more
wiley   +1 more source

RNF187 inhibits porcine reproductive and respiratory syndrome virus replication by recruiting the autophagy receptor NDP52 to degrade nsp12. [PDF]

Vet Res
Wang Q, Zheng G, Tian T, Chen A, Zhang G, Wang H.   +5 more
europepmc   +1 more source

Cefepime exposure in prolonged or intermittent infusion in critically ill children

British Journal of Clinical Pharmacology, EarlyView.
Aims Cefepime is commonly used in critically ill children for whom there is a high between‐subject variability. To reach the therapeutic pharmacokinetic (PK) target in critically ill patients, prolonged infusion of beta‐lactams seems to be the most efficient.
Marc Hobeika, Deborah Hirt, Emmanuelle Bille, Sihem Benaboud, Julie Toubiana, Pierre‐Louis Léger, Jérôme Rambaud, Agathe Béranger, Delphine Callot, Sylvain Renolleau, Jean‐Marc Treluyer, Mehdi Oualha, Noémie de Cacqueray   +12 more
wiley   +1 more source

Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study. [PDF]

Br J Haematol
Wang M, Jurczak W, Trneny M, Belada D, Wrobel T, Ghosh N, Keating MM, van Meerten T, Alvarez RF, von Keudell G, Thieblemont C, Peyrade F, Andre M, Hoffmann M, Szafer-Glusman E, Lin J, Dean JP, Neuenburg JK, Tam CS.   +18 more
europepmc   +1 more source

Analysis of clinical investigation (device) initial submissions received by the Medicines and Healthcare products Regulatory Agency between January 2022 and December 2025

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse clinical investigation‐device initial submissions received by the MHRA between January 2022 and December 2025. Methods Data on submissions were extracted from the clinical investigations unit data bank; software as medical devices were not included. The predefined primary end‐point was submission type.
Andrea Manfrin, Mark Grumbridge, Daniel Hill, Crina Cacou, Graham Warren, James Pound, Jacob George, Alejandro F. Frangi   +7 more
wiley   +1 more source